Ethical Considerations in the Translation of CAR-T Cell TherapiesPublished: May 14, 2018
Latest Advances in CAR-T Cell Manufacture & Clinical Developments
Kathleen J Imbach, Arjun Patel & Aaron D Levine
Despite the enormous promise of chimeric antigen receptor T (CAR-T) cell therapies, the translation and commercialization of these therapies raise a number of pressing ethical questions. These concerns include managing the toxicities associated with these powerful therapies both for research participants in clinical trials and patients receiving approved therapies. The safety concerns are a key issue for the field today but will become even more pressing as CAR-T cell therapies move from their current status as last-resort approaches closer to the therapeutic front-lines. They also include ensuring equitable access to these innovative therapies – along both financial and geographic lines – and managing expectations and patient demands for access to high potential but not yet proven interventions. The article aims to articulate these and other key ethical challenges for the field and suggest some strategies to help navigate these challenges and facilitate the successful translation and commercialization of CAR-T cell therapies.DOI: 10.18609/cgti.2018.030
Citation: Cell Gene Therapy Insights 2018; 4(4), 295-307.